According to the literature, some weak AhR ligands may compete with PAH for binding to the receptor and thus form AhR–ligand complexes with a reduced ability to recruit basic transcription factors to the promoters of target genes, thereby counteracting the effects of PAH on CYP1A [63, 64]. The gene discussed is AHR; the disease is pulmonary arterial hypertension.